Empowering patients as part of a successful biosimilar switching strategy

Listen to Emma Foreman and María-José Tamés as they discuss the importance of patient education concerning treatment regimens involving biosimilars.


Recent studies suggest that the main patient concerns around biosimilar treatments concern safety, efficacy, extrapolation of indications, and potential societal benefits. This webinar aims to educate learners on aspects of effective dissemination of information relating to biosimilars and the patient concerns related to them. The webinar covers the multi-stakeholder approach to patient education and the role that different healthcare practitioners have in determining communication strategies, using specific case examples.

This 30-minute webinar features insights from expert faculty from across the globe as well as audience questions being answered.

Target audience

This educational activity is designed for hospital-based pharmacists and all other healthcare professionals involved in the management of patients with cancer.

Learning objectives

After watching this webinar, viewers will be able to:

  • Discuss the main concerns patients may have about safety, efficacy and the extrapolation of indications of biosimilars
  • Apply effective education strategies for ensuring patient understanding and confidence in the approvals process for biosimilars and what that means for their treatment
  • Discuss the difference in educational requirements for patients new to biologics and patients who are being switched from an originator biologic to a biosimilar

Emma Foreman

Emma Foreman

Consultant Pharmacist
Royal Marsden Hospital, London, UK

María-José Tamés

María-José Tamés

Assistant Director
Onkologikoa Foundation, San Sebastián, Spain